Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor
暂无分享,去创建一个
H. Heyn | C. Lázaro | G. Capellá | A. Villanueva | J. Morata | B. Gel | E. Serra | C. Moutinho | I. Blanco | J. Fernández-Rodríguez | A. Vidal | H. Salvador | L. Farré | F. Soldado | M. Martínez-Iniesta | A. Morales La Madrid | L. Krauel | A. Castañeda Heredia | M. Suñol | Edgar Creus-Bachiller
[1] C. Moiola,et al. Patient-Derived Xenograft Models for Endometrial Cancer Research , 2018, International journal of molecular sciences.
[2] Christopher T. Saunders,et al. Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.
[3] C. Pratilas,et al. The promise of signal transduction in genetically driven sarcomas of the nerve , 2018, Experimental Neurology.
[4] J. Teer,et al. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation , 2017, Scientific Reports.
[5] Steven J. M. Jones,et al. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.
[6] J. Rochaix. The Pyrenoid: An Overlooked Organelle Comes out of Age , 2017, Cell.
[7] S. Sleijfer,et al. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors , 2017, PloS one.
[8] Karlyne M. Reilly,et al. Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future , 2017, Journal of the National Cancer Institute.
[9] Bernat Gel,et al. karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data , 2017, bioRxiv.
[10] K. Reilly,et al. Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies , 2017, Sarcoma.
[11] I. Laurendeau,et al. Confirmation of mutation landscape of NF1‐associated malignant peripheral nerve sheath tumors , 2017, Genes, chromosomes & cancer.
[12] Karen S. Fernández,et al. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single‐center experience , 2017, Pediatric blood & cancer.
[13] N. Ratner,et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.
[14] J. Qi,et al. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma , 2016, Oncogene.
[15] L. Kwong,et al. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models , 2016, Oncotarget.
[16] F. Fazioli,et al. Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma , 2016, Sarcoma.
[17] A. Carnero,et al. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA , 2015, Oncotarget.
[18] O. Merimsky,et al. Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas. , 2015, Molecular and clinical oncology.
[19] X. Puente,et al. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine , 2015, EMBO molecular medicine.
[20] L. Qin,et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors , 2014, Nature Genetics.
[21] M. Esteller,et al. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. , 2014, Cancer research.
[22] Eric Legius,et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.
[23] N. M. Powell,et al. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity , 2014, Oncotarget.
[24] Heng Li. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.
[25] G. Page,et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. , 2013, The Journal of clinical investigation.
[26] M. von Mehren,et al. New drugs and combinations for the treatment of soft-tissue sarcoma: a review , 2012, Cancer management and research.
[27] M. Esteller,et al. Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer , 2012, Clinical Cancer Research.
[28] B. Pockaj,et al. Malignant Peripheral Nerve Sheath Tumors (MPNST): The Mayo Clinic Experience , 2012, Annals of Surgical Oncology.
[29] L. Mariani,et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. , 2011, European journal of cancer.
[30] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[31] R. Maki. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. , 2007, The oncologist.
[32] A. Ferrari,et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] P. Pisters,et al. Combined-modality treatment of localized soft tissue sarcomas of the extremities. , 2003, Surgical oncology clinics of North America.